Tuzi, A. (2013) “Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies”, Radiology and Oncology, 47(1). Available at: https://radioloncol.com/index.php/ro/article/view/728 (Accessed: 10 June 2026).